Row breaks out over German funding of short acting diabetes treatment

doi:10.1136/bmj.332.7546.874-c

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Annette Tuffs

Heidelberg

The German independent Institute for Quality and Economic Efficiency in Health Care has come under fire from doctors, patients, politicians, and the drugs industry for questioning the use of short acting insulin analogues for late onset (type 2) diabetes. The institute is Germany's equivalent of the National Institute for Health and Clinical Excellence (NICE) in England.

Following the institute's report, a federal committee has announced that it intends to forbid health insurance companies from paying for costly short acting insulin analogues rather than insulin.

No other institution in Europe has published recommendations on the use of these drugs, but NICE published recommendations on long acting insulin in December 2002 (www.nice.org.uk/page.aspx?o=43424).

The …